Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RPA1 | P27694 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6886607 | 0.90 | KDM4E (0.53) | KDM4EMEN1MAPTMAPK1KMT2A | |
| Hydrochloric Acid SCHEMBL6770419 | 0.88 | KDM4E (0.52) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL6766067 | 0.82 | MAPT (0.74) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL3828981 | 0.75 | CNR1 (0.68) | CNR1CNR2RPA1 | |
| SCHEMBL13955261 | 0.74 | LMNA (0.59) | CNR1ALDH1A1CNR2LMNA | |
| SCHEMBL8018662 | 0.72 | CNR1 (0.63) | CNR1CNR2 | |
| SCHEMBL3827684 | 0.72 | CNR1 (0.70) | CNR1CNR2 | |
| SCHEMBL13191030 | 0.72 | CNR1 (0.68) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL4481055 | 0.72 | CNR1 (0.72) | CNR1CNR2 | |
| SCHEMBL13664195 | 0.71 | KDM4E (0.50) | KDM4EMEN1MAPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | KDM4E 3327/4885MEN1 4525/4885MAPT 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.